Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Finerenone for progression of non-diabetic chronic kidney disease (Phase 3)
2021-000421-27Phase 3Active
- Sponsor
- Bayer
- Start
- Jul 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in chronic kidney disease (CKD) comparing Finerenone + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Mean rate of change in eGFR. Started Jul 2021; status: active.
02
Drugs
finerenone
03
Conditions
chronic kidney disease (CKD)
Beyond the preview
Go deeper on 2021-000421-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000421-27.